Advanced Solid Tumors Clinical Trials in Chicago, Illinois

8 studies are recruiting for advanced solid tumors in Chicago, Illinois right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors

   This is a first-in-human, Phase I, open-label, multicenter, dose-escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of VVD-133214 monotherapy, and in combination with bevacizumab or pembrolizumab, in part…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Chicago, Chicago, Illinois

   Locations

   47 in total

   Run by

   Vividion Therapeutics, Inc.

   See if you can join NCT06004245 on ClinicalTrials.gov

2. Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors

   The primary objective of this study is to determine the recommended Phase 2 doses (RP2D(s)) and maximum tolerated dose (MTD) of PYX-201 in combination with pembrolizumab for participants with advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Chicago, Chicago, Illinois

   Locations

   22 in total

   Run by

   Pyxis Oncology, Inc

   See if you can join NCT06795412 on ClinicalTrials.gov

3. TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

   The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE: Due to character limits, the arms section does NOT include …

   Stage

   Phase 2

   Ages

   12 and older

   Site

   Cancer Treatment Centers of America-Chicago, Chicago, Illinois

   Locations

   181 in total

   Run by

   American Society of Clinical Oncology

   See if you can join NCT02693535 on ClinicalTrials.gov

4. A Study of PHST001 in Advanced Solid Tumors

   This is a multi-center, first-in-human (FIH), open-label, Phase 1a/1b dose escalation and dose expansion study to assess the safety, PK, pharmacodynamics, and antitumor activity of PHST001 monotherapy (Phase 1a) or in combination with chemotherapy (Phase 1b) in adult participants with advanced rela…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Chicago Medical Center, Chicago, Illinois

   Locations

   20 in total

   Run by

   Pheast Therapeutics

   See if you can join NCT06840886 on ClinicalTrials.gov

5. Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

   The primary goal of this study is to assess the safety and tolerability of mRNA-4359 administered alone and in combination with pembrolizumab or ipilimumab and nivolumab.

   Stage

   Phase 1

   Ages

   12 and older

   Site

   The University of Chicago Medicine, Chicago, Illinois

   Locations

   39 in total

   Run by

   ModernaTX, Inc.

   See if you can join NCT05533697 on ClinicalTrials.gov

6. An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

   The primary objectives of this trial are to: * Characterize the safety and tolerability of TEV-56278 * Determine the Recommended Phase 2 Dose (RP2D) * Evaluate antitumor activity of TEV-56278 (Part 2 only) * Determine the safety and tolerability of TEV-56278 in combination with pembrolizumab * Dete…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Teva Investigational Site 12016, Chicago, Illinois

   Locations

   12 in total

   Run by

   Teva Branded Pharmaceutical Products R&D LLC

   See if you can join NCT06480552 on ClinicalTrials.gov

7. A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body

   This study is researching an experimental drug called REGN10597 alone or in combination with another drug called cemiplimab (called "study drug(s)"). The study is focused on patients with certain solid tumors that are in an advanced stage. The aim of the study is to see how safe, tolerable, and eff…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Chicago, Chicago, Illinois

   Locations

   11 in total

   Run by

   Regeneron Pharmaceuticals

   See if you can join NCT06413680 on ClinicalTrials.gov

8. Study to Evaluate the Pharmacokinetics and Safety of Pralatrexate in Patients With Advanced Solid Tumor or Hematological Malignancy and Either Normal Hepatic Function or Mild, Moderate, or Severe Hepatic Impairment

   This purpose of this study is to help to evaluate the pharmacokinetic (PK) profile of pralatrexate when administered to patients with various degrees of hepatic impairment and to evaluate the safety and establish the dosing recommendations for pralatrexate administered once weekly for 6 weeks of ev…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Northwestern University - Feinberg School of Medicine, Chicago, Illinois

   Locations

   4 in total

   Run by

   Acrotech Biopharma Inc.

   See if you can join NCT07036133 on ClinicalTrials.gov